Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2009

01-11-2009 | Research Articles

Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study

Authors: Lorenzo Alonso, Elena Gallego, Francisco Jesús González, Alfonso Sánchez-Muñoz, Esperanza Torres, Bella Isabel Pajares, Stephanie Leeflang, Camelia Baha

Published in: Clinical and Translational Oncology | Issue 11/2009

Login to get access
Metadata
Title
Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study
Authors
Lorenzo Alonso
Elena Gallego
Francisco Jesús González
Alfonso Sánchez-Muñoz
Esperanza Torres
Bella Isabel Pajares
Stephanie Leeflang
Camelia Baha
Publication date
01-11-2009
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2009
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-009-0437-4

Other articles of this Issue 11/2009

Clinical and Translational Oncology 11/2009 Go to the issue

Educational Series

Animal models of breast cancer for the study of pathogenesis and therapeutic insights

Case Reports

Chylothorax due to metastatic prostate carcinoma: an unusual complication

Educational Series

Telomerase deficiency and cancer susceptibility syndromes

Educational Series

Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

Correspondence

Predictive value of the clinically and scintigraphically important bone lesions in hormone-refractory prostate cancer (HRPC)

News and Views

Nobel Science Prizes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits